Multivalent antibodies: when design surpasses evolution.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Trends in Biotechnology

• Publication date

  2010-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.tibtech.2010.03.007PMID 20447706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Vessels].

  2018cited by this paper
• Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

  2012cited by this paper
• In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice

  2009cited by this paper
• A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

  2009cited by this paper
• Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold.

  2009cited by this paper
• Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand1

  2009cited by this paper
• In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences

  2009cited by this paper
• Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states

  2008cited by this paper
• Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody Specific for the Catalytic Light Chain

  2008cited by this paper
• Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

  2008cited by this paper
• Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.

  2008cited by this paper
• Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis a virus infection in vitro and in vivo

  2008cited by this paper
• Barnase as a New Therapeutic Agent Triggering Apoptosis in Human Cancer Cells

  2008cited by this paper
• OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

  2008cited by this paper
• Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors

  2008cited by this paper
• High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation

  2007cited by this paper
• Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models

  2007cited by this paper
• Antibody constructs in cancer therapy

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

  2007cited by this paper
• Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting

  2007cited by this paper
• Enhanced antiangiogenic therapy with antibody‐collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events

  2006cited by this paper
• Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.

  2006cited by this paper
• Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R*

  2006cited by this paper
• Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins1

  2006cited by this paper
• Anti-OX40 (CD134) Administration to Nonhuman Primates: Immunostimulatory Effects and Toxicokinetic Study

  2006cited by this paper
• A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-α Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia

  2005cited by this paper
• Antibody engineering: facing new challenges in cancer therapy

  2005cited by this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cited by this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cited by this paper
• Engineered antibody fragments and the rise of single domains

  2005cited by this paper
• Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

  2005cited by this paper
• Monoclonal antibody therapy of cancer.

  2005cited by this paper
• TNF/TNFR family members in costimulation of T cell responses.

  2005cited by this paper
• BiTEs: bispecific antibody constructs with unique anti-tumor activity.

  2005cited by this paper
• The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.

  2005cited by this paper
• Engineered single chain antibody fragments for radioimmunotherapy.

  2004cited by this paper
• Antibodies and gene therapy: teaching old 'magic bullets' new tricks.

  2004cited by this paper
• Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format*

  2004cited by this paper
• Recombinant single‐chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor

  2004cited by this paper
• Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.

  2004cited by this paper
• Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• A novel cell binding site in the coiled‐coil domain of laminin involved in capillary morphogenesis

  2003cited by this paper
• Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv.

  2003cited by this paper
• Design of multivalent complexes using the barnase·barstar module

  2003cited by this paper
• Comparison of Recombinant Derivatives of Chimeric TNT-3 Antibody for the Radioimaging of Solid Tumors

  2003cited by this paper
• Engineered antibodies

  2003cited by this paper
• Di-diabody: a novel tetravalent bispecific antibody molecule by design.

  2003cited by this paper
• 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

  2003cited by this paper
• Selective targeted delivery of TNFalpha to tumor blood vessels.

  2003cited by this paper
• The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.

  2003cited by this paper
• Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

  2002cited by this paper
• Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study

  2002cited by this paper
• Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices

  2002cited by this paper
• 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

  2001cited by this paper
• Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

  2001cited by this paper
• Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.

  2001cited by this paper
• Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered Antibodies

  2001cited by this paper
• Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.

  2001cited by this paper
• Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not.

  2001cited by this paper
• Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides*

  2001cited by this paper
• Design and application of diabodies, triabodies and tetrabodies for cancer targeting.

  2001cited by this paper
• A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.

  2001cited by this paper
• Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.

  2000cited by this paper
• Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1

  2000cited by this paper
• High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.

  2000cited by this paper
• Designer genes: recombinant antibody fragments for biological imaging.

  2000cited by this paper
• Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth

  2000cited by this paper
• ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.

  2000cited by this paper
• Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

  1999cited by this paper
• Construction of mono- and bivalent human single-chain Fv fragments against the D antigen in the Rh blood group: multimerization effect on cell agglutination and application to blood typing.

  1998cited by this paper
• Mammalian cell expression of dimeric small immune proteins (SIP).

  1997cited by this paper
• Triabodies: single chain Fv fragments without a linker form trivalent trimers

  1997cited by this paper
• Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.

  1996cited by this paper
• "Diabodies": small bivalent and bispecific antibody fragments.

  1993cited by this paper
• Multiple protein sequence alignment from tertiary structure comparison: Assignment of global and residue confidence levels

  1992cited by this paper
• Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

  1992cited by this paper
• Monoclonal antibody therapy of cancer.

  1990cited by this paper
• The FASEB Journal • Research Communication Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold

  year unknowncited by this paper

• GPA33-Targeted Trimeric Immunotoxin Exhibits Enhanced Antitumor Activity in Human Colorectal Cancer Xenografts

  2026cites this paper
• Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy

  2025cites this paper
• Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical application.

  2025cites this paper
• Trends in nanobody radiotheranostics

  2025cites this paper
• Structure-informed theoretical modeling defines principles governing avidity in bivalent protein interactions

  2025cites this paper
• Synergistic SuFEx-Driven Covalent Cancer Therapy Using a HER2/EGFR Bivalent Affinity Protein Drug.

  2025cites this paper
• Emerging trends and therapeutic applications of monoclonal antibodies.

  2024cites this paper
• Thermodynamics and Kinetics‐Directed Regulation of Nucleic Acid‐Based Molecular Recognition

  2024cites this paper
• Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.

  2024cites this paper
• Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40

  2024cites this paper
• Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage

  2024cites this paper
• Engineered soluble ACE2 receptor: Responding to change with change

  2023cites this paper
• Enhanced diffusion through multivalency

  2023cites this paper
• Programing Chemical Communication: Allostery vs Multivalent Mechanism.

  2023cites this paper
• Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

  2023cites this paper
• Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment

  2023cites this paper
• A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

  2023cites this paper
• Harnessing sortase A transpeptidation for advanced targeted therapeutics and vaccine engineering.

  2023cites this paper
• Nanoparticle delivery through the BBB in central nervous system tuberculosis

  2023cites this paper
• Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization

  2023cites this paper
• Enhancement of electronic effects at a biomolecule-inorganic interface by multivalent interactions.

  2023cites this paper
• Polyvalency: An emerging trend in the development of clinical antibodies.

  2023cites this paper
• Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells

  2023cites this paper
• Multivalent ACE2 engineering—A promising pathway for advanced coronavirus nanomedicine development

  2022cites this paper
• Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo.

  2022cites this paper
• MVsim is a toolset for quantifying and designing multivalent interactions

  2022cites this paper
• Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine.

  2022cites this paper
• Aptamers as promising nanotheranostic tools in the COVID‐19 pandemic era

  2022cites this paper
• Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy

  2022cites this paper
• Critical parameters for design and development of multivalent nanoconstructs: recent trends

  2022cites this paper
• Applications of trimerbodies in cancer immunotherapy.

  2022cites this paper
• Antibody-based radiopharmaceuticals as theranostic agents: an overview.

  2022cites this paper
• π-Clamp-Mediated Homo- and Heterodimerization of Single-Domain Antibodies via Site-Specific Homobifunctional Conjugation

  2022cites this paper
• Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective

  2022cites this paper
• Binding Revisited—Avidity in Cellular Function and Signaling

  2021cites this paper
• Title : Multivalency enhances the specificity of Fc-cytokine fusions 1

  2021cites this paper
• Engineered mRNA and the Rise of Next-Generation Antibodies

  2021cites this paper
• Higher Order Protein Catenation Leads to an Artificial Antibody with Enhanced Affinity and In Vivo Stability.

  2021cites this paper
• Structural basis of an epitope tagging system derived from Haloarcula marismortui bacteriorhodopsin I D94N and its monoclonal antibody GD‐26

  2021cites this paper
• Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy

  2021cites this paper
• MVsim: a toolset for quantifying and designing multivalent interactions

  2021cites this paper
• Multivalent, asymmetric IL-2-Fc fusions provide optimally enhanced regulatory T cell selectivity

  2021cites this paper
• Intratumoural administration and tumour tissue targeting of cancer immunotherapies

  2021cites this paper
• Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

  2021cites this paper
• Antibody-drug discovery

  2021cites this paper
• An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy.

  2021cites this paper
• Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β.

  2021cites this paper
• Designed proteins assemble antibodies into modular nanocages

  2021cites this paper
• DNA Nanostructures: Current Challenges and Opportunities for Cellular Delivery.

  2021cites this paper
• Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR

  2021cites this paper
• Engineering mono- and multi-valent inhibitors on a modular scaffold† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc03175e

  2020cites this paper
• Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats

  2020cites this paper
• Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies

  2020cites this paper
• Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71

  2020cites this paper
• Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain

  2020cites this paper
• “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

  2020cites this paper
• Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• In silico analysis of SARS-CoV-2 spike glycoprotein and insights into antibody binding

  2020cites this paper
• Snake Antivenom: challenges and alternate approaches.

  2020cites this paper
• Nanolipoprotein particles (NLPs) as a delivery platform for Fab based therapeutics.

  2020cites this paper
• When liposomes met antibodies: Drug delivery and beyond.

  2020cites this paper
• Live long and active: Polypeptide-mediated assembly of antibody variable fragments.

  2020cites this paper
• Designed proteins assemble antibodies into modular nanocages

  2020cites this paper
• Characterization of Hagfish (Eptatretus burgeri) Variable Lymphocyte Receptor–Based Antibody and Its Potential Role in the Neutralization of Nervous Necrosis Virus

  2019influential citation
• Unraveling Determinants of Affinity Enhancement in Dimeric Aptamers for a Dimeric Protein

  2019cites this paper
• The Trypanosomal Transferrin Receptor of Trypanosoma Brucei—A Review

  2019cites this paper
• Interplay between ligand mobility and nanoparticle geometry during cellular uptake of PEGylated liposomes and bicelles.

  2019cites this paper
• A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts

  2019cites this paper
• Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.

  2019cites this paper
• Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies

  2019cites this paper
• History of Envenoming Therapy and Current Perspectives

  2019cites this paper
• Improving the Developability of an Antigen Binding Fragment by Aspartate Substitutions.

  2019cites this paper
• The Influence of Dimerization on the Pharmacokinetics and Activity of an Antibacterial Enzyme Lysostaphin

  2019cites this paper
• Influence of carbon source on cell size and production of anti LDL (-) single-chain variable fragment by a recombinant Pichia pastoris strain

  2019cites this paper
• Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

  2019cites this paper
• Surfaceome nanoscale organization and extracellular interaction networks.

  2019cites this paper
• Freezing-assisted synthesis of covalent C-C linked bivalent and bispecific nanobodies.

  2019cites this paper
• Multivalency in Drug Delivery-When Is It Too Much of a Good Thing?

  2019cites this paper
• [Antibodies, tools of choice for fluorescence-guided surgery].

  2019cites this paper
• Mechanisms of noncanonical binding dynamics in multivalent protein–protein interactions

  2019cites this paper
• A dimeric form of a small‐sized protein binder exhibits enhanced anti‐tumor activity through prolonged blood circulation

  2018cites this paper
• Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily.

  2018cites this paper
• Multivalent Antibody-Nanoparticle Conjugates To Enhance the Sensitivity of Surface-Enhanced Raman Scattering-Based Immunoassays.

  2018cites this paper
• Quantitative Prediction of Multivalent Ligand-Receptor Binding Affinities for Influenza, Cholera, and Anthrax Inhibition.

  2018cites this paper
• Nanobodies and Cancer: Current Status and New Perspectives

  2018cites this paper
• Dual functionality of lamprey VLRB C‐terminus (LC) for multimerization and cell surface display

  2018cites this paper
• A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system

  2018cites this paper
• Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry

  2018cites this paper
• Immunochemical techniques for multianalyte analysis of chemical residues in food and the environment: A review

  2017cites this paper
• An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.

  2017cites this paper
• Engineered ligand‐based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis

  2017cites this paper
• SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery.

  2017cites this paper
• Long‐term regulation of gene expression in muscle cells by systemically delivered siRNA

  2017cites this paper
• Unique therapeutic properties and preparation methodology of multivalent rituximab‐lipid nanoparticles

  2017cites this paper
• Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity

  2017cites this paper
• Expression of Functional Anti-p24 scFv 183-H12-5C in HEK293T and Jurkat T Cells

  2017cites this paper
• Immunoglobulin G (IgG)-Based Imaging Probe Accumulates in M1 Macrophage-Infiltrated Atherosclerotic Plaques Independent of IgG Target Molecule Expression

  2017cites this paper
• Engineering Bifunctional Antibodies with Constant Region Fusion Architectures.

  2017cites this paper